We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


PolyTherics Granted Further Patents for TheraPEG™ and GlycoPol™

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

PolyTherics Limited has strengthened its intellectual property estate with the granting of further patents for TheraPEG™, its site-specific conjugation technology, in Australia and Japan; and for GlycoPol™, a glycopolymer for targeted delivery of biotherapeutics, in the US.

PolyTherics has successfully applied its TheraPEG™ disulfide-bridging conjugation technology to a range of proteins and peptides, including interferons, blood factors and a variety of antibody formats, to either attach poly(ethylene)glycol to extend their duration of action or to produce a protein drug conjugate for targeted delivery.

The granting of the TheraPEG™ patents provides PolyTherics with coverage for its intellectual property in two important markets.

As with TheraPEG™ patents in other major markets the patent in Australia has broad application and covers products conjugated using TheraPEG™, its reagents and the conjugation process.

The granting of the US patent for GlycoPol™, a novel glycopolymer for targeted delivery of therapeutic agents, is a significant milestone for the Company.

GlycoPol™ is a new addition to PolyTherics’ technology offering and was obtained through the acquisition of Warwick Effect Polymers in January 2012.

PolyTherics is currently collaborating with several biotech companies and a top five pharma company in the application of GlycoPol™ for targeted delivery of a range of biotherapeutics.